The Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities - TESLA Part B

Description:

Patients with homozygous familial hypercholesterolemia have markedly elevated low-density lipoprotein cholesterol (LDL-C) and early cardiovascular disease. Statins typically reduce LDL-C in such patients by 22-25%. The current trial sought to assess the safety and efficacy of evolocumab, a PCSK9 inhibitor, to further reduce LDL levels in patients with homozygous familial hypercholesterolemia on lipid-lowering therapy.